Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network
Background Safety of dupilumab in atopic dermatitis (AD) was investigated in randomized controlled trials (RCT). However, head-to-head trials comparing with conventional systemic drugs are lacking and large real-world data on the long-term safety profile as compared are scarce.Objective To compare l...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2421429 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846119652471603200 |
|---|---|
| author | Henner Zirpel Ralf J. Ludwig Henning Olbrich Khalaf Kridin Sascha Ständer Diamant Thaçi |
| author_facet | Henner Zirpel Ralf J. Ludwig Henning Olbrich Khalaf Kridin Sascha Ständer Diamant Thaçi |
| author_sort | Henner Zirpel |
| collection | DOAJ |
| description | Background Safety of dupilumab in atopic dermatitis (AD) was investigated in randomized controlled trials (RCT). However, head-to-head trials comparing with conventional systemic drugs are lacking and large real-world data on the long-term safety profile as compared are scarce.Objective To compare long-term safety profile of dupilumab with conventional systemic drugs used in the management of moderate to severe AD.Methods Data from electronic health records of AD patients treated with either dupilumab, azathioprine, Cyclosporine A, mycophenolate mofetil, methotrexate, or oral glucocorticoids were retrieved from the TriNetX US Collaborative Network. Risks of adverse events and new onset of type-2-inflammatory diseases within 5 years after treatment initiation was investigated.Results 5 propensity-matched cohorts, up to 18,708 individuals per cohort, were created. Dupilumab treatment displayed reduced risk for diseases of the circulatory, the upper respiratory, and the musculoskeletal system, infections, and type 2 diseases as compared to all other treatment options. In contrast risk for conjunctivitis was increased in dupilumab treated patients as compared to mycophenolate mofetil and methotrexate.Conclusion Here presented data indicates that treatment with dupilumab for AD has reduced risk for adverse effects of conventional systemic drugs and thus might be safer. Obtained data should be verified in prospective studies. |
| format | Article |
| id | doaj-art-cd4d5731e7be4858a0f0ed66af78e90a |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-cd4d5731e7be4858a0f0ed66af78e90a2024-12-16T22:53:48ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2421429Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US networkHenner Zirpel0Ralf J. Ludwig1Henning Olbrich2Khalaf Kridin3Sascha Ständer4Diamant Thaçi5Institute and Comprehensive Center for Inflammation Medicine, University-Hospital Lübeck, Lübeck, GermanyLübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, GermanyLübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, GermanyLübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, GermanyInstitute and Comprehensive Center for Inflammation Medicine, University-Hospital Lübeck, Lübeck, GermanyInstitute and Comprehensive Center for Inflammation Medicine, University-Hospital Lübeck, Lübeck, GermanyBackground Safety of dupilumab in atopic dermatitis (AD) was investigated in randomized controlled trials (RCT). However, head-to-head trials comparing with conventional systemic drugs are lacking and large real-world data on the long-term safety profile as compared are scarce.Objective To compare long-term safety profile of dupilumab with conventional systemic drugs used in the management of moderate to severe AD.Methods Data from electronic health records of AD patients treated with either dupilumab, azathioprine, Cyclosporine A, mycophenolate mofetil, methotrexate, or oral glucocorticoids were retrieved from the TriNetX US Collaborative Network. Risks of adverse events and new onset of type-2-inflammatory diseases within 5 years after treatment initiation was investigated.Results 5 propensity-matched cohorts, up to 18,708 individuals per cohort, were created. Dupilumab treatment displayed reduced risk for diseases of the circulatory, the upper respiratory, and the musculoskeletal system, infections, and type 2 diseases as compared to all other treatment options. In contrast risk for conjunctivitis was increased in dupilumab treated patients as compared to mycophenolate mofetil and methotrexate.Conclusion Here presented data indicates that treatment with dupilumab for AD has reduced risk for adverse effects of conventional systemic drugs and thus might be safer. Obtained data should be verified in prospective studies.https://www.tandfonline.com/doi/10.1080/09546634.2024.2421429Atopic dermatitisdupilumabsafetyriskcomorbiditiesconventional systemic therapy |
| spellingShingle | Henner Zirpel Ralf J. Ludwig Henning Olbrich Khalaf Kridin Sascha Ständer Diamant Thaçi Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network Journal of Dermatological Treatment Atopic dermatitis dupilumab safety risk comorbidities conventional systemic therapy |
| title | Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network |
| title_full | Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network |
| title_fullStr | Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network |
| title_full_unstemmed | Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network |
| title_short | Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network |
| title_sort | comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment real world data from the us network |
| topic | Atopic dermatitis dupilumab safety risk comorbidities conventional systemic therapy |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2421429 |
| work_keys_str_mv | AT hennerzirpel comparisonofsafetyprofileinpatientswithatopicdermatitistreatedwithdupilumaborconventionalsystemictreatmentrealworlddatafromtheusnetwork AT ralfjludwig comparisonofsafetyprofileinpatientswithatopicdermatitistreatedwithdupilumaborconventionalsystemictreatmentrealworlddatafromtheusnetwork AT henningolbrich comparisonofsafetyprofileinpatientswithatopicdermatitistreatedwithdupilumaborconventionalsystemictreatmentrealworlddatafromtheusnetwork AT khalafkridin comparisonofsafetyprofileinpatientswithatopicdermatitistreatedwithdupilumaborconventionalsystemictreatmentrealworlddatafromtheusnetwork AT saschastander comparisonofsafetyprofileinpatientswithatopicdermatitistreatedwithdupilumaborconventionalsystemictreatmentrealworlddatafromtheusnetwork AT diamantthaci comparisonofsafetyprofileinpatientswithatopicdermatitistreatedwithdupilumaborconventionalsystemictreatmentrealworlddatafromtheusnetwork |